GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹800 Cr | ₹1,063 Cr | ₹337 Cr | ₹361 Cr | ₹384 Cr |
What is the latest Contingent Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹800 Cr |
| Mar2024 | ₹1,063 Cr |
| Mar2023 | ₹337 Cr |
| Mar2022 | ₹361 Cr |
| Mar2021 | ₹384 Cr |
How is Contingent Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹800 Cr | -24.74 | |
| Mar2024 | ₹1,063 Cr | 215.81 | |
| Mar2023 | ₹337 Cr | -6.81 | |
| Mar2022 | ₹361 Cr | -5.96 | |
| Mar2021 | ₹384 Cr | - | |
Compare Contingent Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹61,927.4 Cr | -2.1% | 1.9% | -1.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹473,509.0 Cr | 0.6% | 6% | 14.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹196,881.0 Cr | 1.2% | 10.5% | 7.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,832.0 Cr | -0.4% | 11% | 40.8% | Stock Analytics | |
| CIPLA | ₹113,894.0 Cr | -1.6% | -2.1% | -4.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,062.8 Cr | -4.6% | -14.8% | -8.4% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -2.1% |
1.9% |
-1.3% |
| SENSEX | -1.1% |
-0.2% |
-6.6% |
You may also like the below Video Courses